perindoprilat has been researched along with valsartan in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Flavahan, NA; Flavahan, S; Leung, SW; Vanhoutte, PM; Xu, A; Zhao, Y | 1 |
| Chang, F; Flavahan, NA; Flavahan, S | 1 |
3 other study(ies) available for perindoprilat and valsartan
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Elevated pressure causes endothelial dysfunction in mouse carotid arteries by increasing local angiotensin signaling.
Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Carotid Arteries; Endothelium, Vascular; Hydrazines; Hypertension; Indoles; Losartan; Male; Mice; Mice, Inbred C57BL; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Reactive Oxygen Species; Signal Transduction; Tetrazoles; Valine; Valsartan; Vasodilation | 2015 |
Local renin-angiotensin system mediates endothelial dilator dysfunction in aging arteries.
Topics: Adrenergic alpha-1 Receptor Agonists; Aging; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arteries; Endothelium, Vascular; Enzyme Inhibitors; Fumarates; Indoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Phenylephrine; Rats; Rats, Inbred F344; Renin; Renin-Angiotensin System; Valsartan; Vasodilation | 2016 |